MRNA-Based Therapeutics
- 1st Edition, Volume 372 - September 3, 2022
- Imprint: Academic Press
- Editors: Fernando Aranda Vega, Pedro Berraondo, Lorenzo Galluzzi
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 9 9 4 0 1 - 9
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 9 4 0 9 - 5
MRNA-Based Therapeutics, Volume 372 in the International Review of Cell and Molecular Biology series, covers topics surrounding the effect of different metabolic situations, t… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteMRNA-Based Therapeutics, Volume 372 in the International Review of Cell and Molecular Biology series, covers topics surrounding the effect of different metabolic situations, their contribution to metabolic modulation, and their impact on tumor growth. Specific chapters in this release include New era of nucleic acid therapies: Clinical applications and perspectives, Messenger RNA as personalized therapy: time of truth for rare metabolic disease, Applications of Self-Replicating RNA, mRNA therapy in PKU, Advances in gene-editing technologies, mRNA delivery technologies: towards clinical translation, Advances in mRNA vaccines, and more.
- Provides the authority and expertise of leading contributors from an international board of authors
- Presents the latest release in International Review of Cell and Molecular Biology serials
- Updated release includes the latest information on MRNA-Based Therapeutics
Academic, government and industrial sectors
- Cover
- Title page
- Table of Contents
- Copyright
- Contributors
- Chapter One: mRNA-based therapies: Preclinical and clinical applications
- Abstract
- 1: Introduction
- 2: Chemical modifications
- 3: Preclinical and clinical applications of IVT mRNA
- 4: Conclusions and future perspectives
- Conflict of interest disclosure
- References
- Chapter Two: Messenger RNA as a personalized therapy: The moment of truth for rare metabolic diseases
- Abstract
- 1: Introduction
- 2: mRNA therapeutics vs other advanced therapies for liver metabolic diseases
- 3: Conclusions and perspectives
- References
- Chapter Three: Applications of self-replicating RNA
- Abstract
- 1: Introduction
- 2: Self-replicating RNA vectors
- 3: Self-replicating RNA for infectious diseases
- 4: Self-replicating RNA for cancer therapy
- 5: Conclusions
- References
- Chapter Four: Present and future of lipid nanoparticle-mRNA technology in phenylketonuria disease treatment
- Abstract
- 1: Introduction
- 2: Replacement therapies for PKU
- 3: Emerging strategy: Genome editing on PKU
- 4: Future perspective
- Acknowledgments and declaration of interests
- References
- Further reading
- Chapter Five: RNA gene editing in the eye and beyond: The neglected tool of the gene editing armatorium?
- Abstract
- 1: Introduction
- 2: The advent of ADAR
- 3: RNA editing in the eye
- 4: Challenges and pitfalls
- 5: Conclusion
- Acknowledgments
- References
- Chapter Six: mRNA delivery technologies: Toward clinical translation
- Abstract
- 1: Introduction
- 2: Synthetic mRNA
- 3: mRNA delivery systems
- 4: Clinical applications of mRNA
- 5: Conclusions
- Acknowledgments
- References
- Chapter Seven: Advances in mRNA vaccines
- Abstract
- 1: Messenger RNA synthesis and modification for vaccine
- 2: Carrier-mediated mRNA vaccine delivery
- 3: mRNA vaccines for clinical applications
- References
- Edition: 1
- Volume: 372
- Published: September 3, 2022
- Imprint: Academic Press
- No. of pages: 326
- Language: English
- Hardback ISBN: 9780323994019
- eBook ISBN: 9780323994095
FA
Fernando Aranda Vega
Fernando Aranda holds a BSc in Biology (2006) and Biochemistry (2007) from the University of Navarra. Then, he specialized in different strategies of Cancer Immunotherapy with a MSc in Biomedical Research (2008), and a PhD Degree (2012) from the University of Navarra (Pamplona) – Cima University of Navarra. More than 12 years in translational research focus on antitumor immune responses and Cancer Immunotherapy. Author of 64 publications indexed in PubMed in prestigious international journals, with h-index 30 and 4,296 cites (October 2022). He completed the Program of Sara Borrell (ISCIII) -competitive Postdoctoral contract- in the Group of Immune Receptors of the Innate and Adaptive System (IDIBAPS), Barcelona (2016-2018). Co-author of 1 invention patent: Composition based on the fibronectin domain A for the treatment of melanoma - WO/2011/101332. In 2012, Fernando Aranda obtained a Scientific Award, "Profesor Durantez" II Edición, for the best scientific article in Tumor Immunology by Fundación LAIR. Recently, Fernando Aranda awarded a competitive Research Fellow contract “Miguel Servet tipo I” by Instituto de Salud Carlos III, to continue his independent researcher career (IP) in cancer immunotherapy issues. Specifically, he is involved in Translational Immunotherapy of Peritoneal Carcinomatosis. Currently, Fernando Aranda leads a research group in cooperation with Dr. Pedro Berraondo.
Affiliations and expertise
Fernando Aranda Vega, CIMA Universidad de Navarra, Program of Immunology and Immunotherapy, SpainPB
Pedro Berraondo
Pedro Berraondo graduated in Pharmacy at the University of Navarra in 1999. In 2004 he obtained the Ph.D. at the same university. Next, he worked at the Pasteur Institute in Paris (France) under the supervision of Dr. Claude Leclerc, where he developed novel strategies in tumor immunotherapy within the European THERAVAC project. In February 2007, he joined the Immunology and Immunotherapy Program at the Cima Universidad de Navarra, where he leads the Cytokine-based Immunotherapy laboratory. He is co-inventor of ten patents and he is co-author of more than 140 publications, including publications in Nature, Nature Medicine, Nature Reviews Drug Discovery, Immunity, Cancer Discovery, and Cancer Cell. He was certified as a full professor in 2021 by AQU. He is co-director of the degree of expert in immunooncology at the Faculty of Medicine of the University of Navarra, and is in charge of the undergraduate course of macromolecular structure at the Faculty of Sciences of the University of Navarra. He is also the coordinator of the immuno-oncology work module at CIBERONC.
Affiliations and expertise
CIMA Universidad de Navarra, Program of Immunology and Immunotherapy, SpainLG
Lorenzo Galluzzi
Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza”. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology.
Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals:
OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience.
Affiliations and expertise
Assistant Professor of Cell Biology in Radiation Oncology, Department of Radiation Oncology, Weill Cornell Medical College, NY, USARead MRNA-Based Therapeutics on ScienceDirect